Near Full-length Genomic Sequencing and Molecular Analysis of HIV-Infected Individuals in a Network-based Intervention (TRIP) in Athens, Greece: Evidence that Transmissions Occur More Frequently from those with High HIV-RNA

Author(s): Evangelia-Georgia Kostaki, Daniel Frampton, Dimitrios Paraskevis, Katerina Pantavou, Bridget Ferns, Jade Raffle, Paul Grant, Zisis Kozlakidis, Andria Hadjikou, Eirini Pavlitina, Leslie D. Williams, Angelos Hatzakis, Samuel R. Friedman, Eleni Nastouli, Georgios K. Nikolopoulos*.

Journal Name: Current HIV Research

Volume 16 , Issue 5 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: TRIP (Transmission Reduction Intervention Project) was a network-based, contact tracing approach to locate and link to care, mostly people who inject drugs (PWID) with recent HIV infection.

Objective: We investigated whether sequences from HIV-infected participants with high viral load cluster together more frequently than what is expected by chance.

Methods: Paired end reads were generated for 104 samples using Illumina MiSeq next-generation sequencing.

Results: 63 sequences belonged to previously identified local transmission networks of PWID (LTNs) of an HIV outbreak in Athens, Greece. For two HIV-RNA cut-offs (105 and 106 IU/mL), HIV transmissions were more likely between PWID with similar levels of HIV-RNA (p<0.001). 10 of the 14 sequences (71.4%) from PWID with HIV-RNA >106 IU/mL were clustered in 5 pairs. For 4 of these clusters (80%), there was in each one of them at least one sequence from a recently HIVinfected PWID.

Conclusion: We showed that transmissions are more likely among PWID with high viremia.

Keywords: HIV, recent infection, HIV transmission, PWID, HIV-RNA, TRIP.

[1]
Bekker L-G, Beyrer C, Quinn TC. Behavioral and biomedical combination strategies for HIV prevention. Cold Spring Harb Perspect Med 2012; 2: a007435.
[2]
Latkin CA, Davey-Rothwell MA, Knowlton AR, et al. Social network approaches to recruitment, HIV prevention, medical care, and medication adherence. J Acquir Immune Defic Syndr 2013; 63(Suppl. 1): S54-8.
[3]
Ghosh D, Krishnan A, Gibson B, et al. Social network strategies to address HIV prevention and treatment continuum of care among at-risk and HIV-infected substance users: A systematic scoping review. AIDS Behav 2017; 21: 1183-207.
[4]
Friedman SR, Kottiri BJ, Neaigus A, et al. Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population-group saturation. Am J Epidemiol 2000; 152: 913-22.
[5]
Dombrowski K, Khan B, Habecker P, et al. The interaction of risk network structures and virus natural history in the non-spreading of HIV among people who inject drugs in the early stages of the epidemic. AIDS Behav 2017; 21: 1004-15.
[6]
Friedman SR, Neaigus A, Jose B, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health 1997; 87: 1289-96.
[7]
Johnson BT, Redding CA, DiClemente RJ, et al. A Network-individual-resource model for HIV prevention. AIDS Behav 2010; 14: 204-21.
[8]
Amirkhanian YA, Kelly JA, Kabakchieva E, et al. A randomized social network HIV prevention trial with young men who have sex with men in Russia and Bulgaria. AIDS 2005; 19: 1897-905.
[9]
Latkin CA, Knowlton AR. Micro-social structural approaches to HIV prevention: a social ecological perspective. AIDS Care 2005; 17: 102-13.
[10]
Nikolopoulos G, Pavlitina E, Muth S, et al. A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP). Sci Rep 2016; 6: 38100.
[11]
Hull MW, Montaner J. Antiretroviral therapy: A key component of a comprehensive HIV prevention strategy. Curr HIV/AIDS Rep 2011; 8: 85-93.
[12]
Hull MW, Montaner JSG. HIV treatment as prevention: The key to an AIDS-free generation. J Food Drug Anal 2013; 21: S95-S101.
[13]
Tymejczyk O, Jamison K, Pathela P, et al. HIV Care and Viral Load Suppression After Sexual Health Clinic Visits by Out-of-Care HIV-Positive Persons. AIDS Patient Care STDS 2018; 32: 390-8.
[14]
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-9.
[15]
Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29: 275-83.
[16]
Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012; 205: 358-65.
[17]
Zheng Z, Li Y, Jiang Y, et al. Population HIV transmission risk for serodiscordant couples in Guangxi, Southern China: A cohort study. Medicine (Baltimore) 2018; 97(36): e12077.
[18]
Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010; 5: e12598.
[19]
Montain J, Ti L, Hayashi K, et al. Impact of length of injecting career on HIV incidence among people who inject drugs. Addict Behav 2016; 58: 90-4.
[20]
Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338: b1649.
[21]
Del Romero J, Río I, Castilla J, et al. Absence of transmission from HIV-infected individuals with HAART to their heterosexual serodiscordant partners. Enferm Infecc Microbiol Clin 2015; 33: 666-72.
[22]
Pedraza MA, del Romero J, Roldán F, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999; 21: 120-5.
[23]
Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-8.
[24]
Murnane PM, Hughes JP, Celum C, et al. Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission. PLoS One 2012; 7: e51192.
[25]
Loutfy MR, Wu W, Letchumanan M, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One 2013; 8: e55747.
[26]
Spittal PM, Craib KJP, Wood E, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ 2002; 166: 894-9.
[27]
Kerr T, Marshall BDL, Milloy M-J, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend 2012; 124: 108-12.
[28]
Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV‐1 transmission per coital act, by stage of HIV‐1 infection, in Rakai, Uganda. J Infect Dis 2005; 191: 1403-9.
[29]
Cohen MS, Smith MK, Muessig KE, et al. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet 2013; 382: 1515-24.
[30]
Brown A, Gill O, Delpech V. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med 2013; 14: 563-70.
[31]
Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. JAMA 2013; 310: 1619.
[32]
Solomon SS, Mehta SH, McFall AM, et al. Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study. Lancet HIV 2016; 3: e183-90.
[33]
Cohen MS, Gay CL. Treatment to prevent transmission of HIV‐1. Clin Infect Dis 2010; 50: S85-95.
[34]
Fiebig E, Wright D, Rawal B, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2013; 17: 1871-9.
[35]
Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198: 687-93.
[36]
Leynaert B n d., Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: Variability of infectivity throughout the course of infection. Am J Epidemiol 1998; 148: 88-96.
[37]
Bellan SE, Dushoff J, Galvani AP, et al. Reassessment of HIV-1 acute phase infectivity: Accounting for heterogeneity and study design with simulated cohorts. PLoS Med 2015; 12: e1001801.
[38]
Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149-53.
[39]
Serwadda D, Gray RH, Wawer MJ, et al. The social dynamics of HIV transmission as reflected through discordant couples in rural Uganda. AIDS 1995; 9: 745-50.
[40]
Kiwanuka N, Laeyendecker O, Quinn TC, et al. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS 2009; 23: 2479-84.
[41]
Safren SA, Mayer KH, Ou S-S, et al. Adherence to early antiretroviral therapy: Results from HPTN 052, a phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples. J Acquir Immune Defic Syndr 2015; 69: 234-40.
[42]
Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS 2012; 26: 2079-86.
[43]
Brenner BG, Roger M, Routy J, et al. High rates of forward transmission events after acute/early HIV‐1 infection. J Infect Dis 2007; 195: 951-9.
[44]
Escudero DJ, Lurie MN, Mayer KH, et al. The risk of HIV transmission at each step of the HIV care continuum among people who inject drugs: a modeling study. BMC Public Health 2017; 17: 614.
[45]
Paraskevis D, Kostaki E, Nikolopoulos GK, et al. Molecular tracing of the geographical origin of human immunodeficiency virus type 1 infection and patterns of epidemic spread among migrants who inject drugs in athens. Clin Infect Dis 2017; 65: 2078-84.
[46]
Paraskevis D, Kostaki E, Magiorkinis G, et al. Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003-2015: Transmitted drug resistance is due to onward transmissions. Infect Genet Evol 2017; 54: 183-91.
[47]
Vasylyeva TI, Friedman SR, Lourenco J, et al. Reducing HIV infection in people who inject drugs is impossible without targeting recently-infected subjects. AIDS 2016; 30: 2885-90.
[48]
Drescher SM, von Wyl V, Yang W-L, et al. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the swiss HIV cohort study. Clin Infect Dis 2014; 58: 285-94.
[49]
Yerly S, Junier T, Gayet-Ageron A, et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009; 23: 1415-23.
[50]
Paraskevis D, Nikolopoulos GK, Magiorkinis G, et al. The application of HIV molecular epidemiology to public health. Infect Genet Evol 2016; 46: 159-68.
[51]
Audelin AM, Cowan SA, Obel N, et al. Phylogenetics of the Danish HIV epidemic. JAIDS J Acquir Immune Defic Syndr 2013; 62: 102-8.
[52]
Kouyos RD, von Wyl V, Yerly S, et al. Molecular epidemiology reveals long‐term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 2010; 201: 1488-97.
[53]
Lourenço L, Colley G, Nosyk B, et al. High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada. PLoS One 2014; 9: e115277.
[54]
Vasylyeva TI, Liulchuk M, Friedman SR, et al. Molecular epidemiology reveals the role of war in the spread of HIV in Ukraine. Proc Natl Acad Sci USA 2018; 115: 1051-6.
[55]
Nikolopoulos GK, Katsoulidou A, Kantzanou M, et al. Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece. Epidemiol Infect 2017; 145: 401-12.
[56]
Yebra G, Frampton D, Gallo Cassarino T, et al. A high HIV-1 strain variability in London, UK, revealed by full-genome analysis: Results from the ICONIC project. PLoS One 2018; 13: e0192081.
[57]
Yebra G, Hodcroft EB, Ragonnet-Cronin ML, et al. Using nearly full-genome HIV sequence data improves phylogeny reconstruction in a simulated epidemic. Sci Rep 2016; 6: 39489.
[58]
Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73: 152-60.
[59]
Chu C, Selwyn P. Diagnosis and initial management of acute HIV infection. Am Fam Physician 2010; 81: 1239-44.
[60]
Stamatakis A. Raxml version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 2014; 30: 1312-3.
[61]
Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5: e9490.
[62]
Kostaki E, Magiorkinis G, Psichogiou M, et al. Detailed molecular surveillance of the HIV-1 outbreak among people who inject drugs (PWID) in Athens during a period of four years. Curr HIV Res 2017; 15(6): 396-404.
[63]
Maddison W. Mesquite: A modular system for evolutionary analysis Version 350 2018.
[64]
Paraskevis D, Nikolopoulos G, Fotiou A, et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One 2013; 8: e78941.
[65]
Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav 2008; 12: 677-84.
[66]
Miller WC, Rosenberg NE, Rutstein SE, et al. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5: 277-82.
[67]
Campbell EM, Jia H, Shankar A, et al. Detailed transmission network analysis of a large opiate-driven outbreak of HIV infection in the United States. J Infect Dis 2017; 216: 1053-62.
[68]
Niculescu I, Paraschiv S, Paraskevis D, et al. Recent HIV-1 outbreak among intravenous drug users in romania: Evidence for cocirculation of CRF14_BG and subtype F1 strains. AIDS Res Hum Retroviruses 2015; 31: 488-95.
[69]
Ragonnet-Cronin M, Jackson C, Bradley-Stewart A, et al. Recent and rapid transmission of HIV among people who inject drugs in scotland revealed through phylogenetic analysis. J Infect Dis 2018; 217: 1875-82.
[70]
Paraskevis D, Nikolopoulos GK, Sypsa V, et al. Molecular investigation of HIV-1 cross-group transmissions during an outbreak among people who inject drugs (2011-2014) in Athens, Greece. Infect Genet Evol 62: 11-6.
[71]
Paraskevis D, Nikolopoulos G, Tsiara C, et al. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. EuroSurveill 2011 16: pii: 19962.
[72]
Kostaki E-G, Nikolopoulos GK, Pavlitina E, et al. Molecular analysis of human immunodeficiency virus type 1 (HIV-1)-infected individuals in a network-based intervention (Transmission Reduction Intervention Project): Phylogenetics identify HIV-1-infected individuals with social links. J Infect Dis 2018; 218: 707-15.
[73]
Kostaki E-G, Karamitros T, Bobkova M, et al. Spatiotemporal characteristics of the HIV-1 CRF02_AG/CRF63_02A1 epidemic in Russia and central Asia. AIDS Res Hum Retroviruses 2018; 34: 415-20.
[74]
Nikolopoulos GK, Kostaki E-G, Paraskevis D. Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia. Infect Genet Evol 2016; 46: 256-68.
[75]
Sallam M, Esbjörnsson J, Baldvinsdóttir G, et al. Molecular epidemiology of HIV-1 in Iceland: Early introductions, transmission dynamics and recent outbreaks among injection drug users. Infect Genet Evol 2017; 49: 157-63.
[76]
Paraschiv S, Banica L, Nicolae I, et al. Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users. PLoS One 2017; 12: e0185866.
[77]
Mozhgani S-H, Ebrahimian SA, Gudarzi H, et al. CRF35-AD as the main circulating genotype of human immunodeficiency virus type 1 infection in Iran: A phylogenetic and demographic-based study. Intervirology 2017; 60: 144-8.
[78]
Alexiev I, Shankar A, Dimitrova R, et al. Origin and spread of HIV-1 in persons who inject drugs in Bulgaria. Infect Genet Evol 2016; 46: 269-78.
[79]
Peters PJ, Pontones P, Hoover KW, et al. HIV Infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med 2016; 375: 229-39.
[80]
da Silva França DD, Del-Rios NHA. Carneiro MA dos S, et al. HIV-1 infection among crack cocaine users in a region far from the epicenter of the HIV epidemic in Brazil: Prevalence and molecular characteristics. PLoS One 2018; 13: e0199606.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 5
Year: 2018
Page: [345 - 353]
Pages: 9
DOI: 10.2174/1570162X17666190130120757

Article Metrics

PDF: 33
HTML: 5
EPUB: 1
PRC: 1